|
Investigation of clinical and laboratory symptoms of drug-induced lupus in patients over 20 years old with inflammatory rheumatic diseases using anti-TNFα, referring to BooAli Hospital in Tehran during the years 2020-2023
|
Parivash Fadaei Zadeh Bidari1    , Shahla Abolghasemi2 , Shima Mosalanejad1 , Mehdi Afkar3 |
1- Internal Medicine Resident, Department of Internal Diseases, TeMS.C., Islamic Azad University, Tehran, Iran
2- Assistant Professor, Department of Rheumatology, TeMS.C., Islamic Azad University, Tehran, Iran , Abolghasemishahla129@gmail.com
3- Specialist in Social Medicine, Department of Social Medicine, TeMS.C., Islamic Azad University, Tehran, Iran |
|
|
Abstract: (87 Views) |
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of autoantibodies against nuclear antigens. Drug-induced lupus erythematosus (DILE) is a type of SLE that occurs as a result of the prolonged use of certain medications, including anti-tumor necrosis factor alpha (anti-TNFα) agents. This study aimed to investigate the clinical and laboratory manifestations of drug-induced lupus in individuals over 20 years of age with inflammatory rheumatologic diseases treated with anti-TNFα at BooAli Hospital in Tehran.
Materials and methods: This cross-sectional, descriptive-analytical study was conducted on 46 patients (13 men and 33 women) with a mean age of 55 years. Patients had rheumatoid arthritis, psoriasis, or spondyloarthropathy and had been suffering from their disease for at least one year. Clinical and laboratory assessments were performed before and six months after the initiation of treatment with etanercept or adalimumab.
Results: After six months of treatment with anti-TNFα, no clinical manifestations related to DILE were observed. The frequency of patients with positive ANA significantly increased from 17.39% to 32.60%. Other laboratory parameters did not show significant changes. A significant decrease in RF and Anti-CCP levels was observed, indicating suppression of the inflammatory process.
Conclusion: Treatment with anti-TNFα in patients with inflammatory rheumatic diseases leads to an increase in positive ANA, but this increase does not lead to the clinical manifestations of DILE. The decrease in RF and Anti-CCP levels indicates the effectiveness of the treatment in controlling disease activity.
|
|
| Keywords: Systemic lupus erythematosus (SLE), Drug-induced lupus (DILE), Etanercept, Adalimumab, Inflammatory rheumatic diseases |
|
|
Full-Text [PDF 843 kb]
(7 Downloads)
|
Semi-pilot: Survey/Cross Sectional/Descriptive |
Subject:
Romatology
Received: 2024/09/24 | Accepted: 2024/11/25 | Published: 2025/05/31
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
